- Home
- BSM vs LEGN Comparison
BSM vs LEGN Comparison
Compare BSM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSM | LEGN |
|---|---|---|
| Founded | 1876 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.6B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BSM | LEGN |
|---|---|---|
| Price | $14.74 | $19.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $45.62 |
| AVG Volume (30 Days) | 322.8K | ★ 2.0M |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | ★ 8.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $469,919,000.00 | N/A |
| Revenue This Year | $13.26 | $39.73 |
| Revenue Next Year | $7.88 | $23.42 |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | ★ 8.35 | N/A |
| 52 Week Low | $12.36 | $16.24 |
| 52 Week High | $15.49 | $37.50 |
Technical Indicators
Market Signals| Indicator | BSM | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 55.45 |
| Support Level | $14.66 | $19.71 |
| Resistance Level | $15.20 | $19.92 |
| Average True Range (ATR) | 0.20 | 0.82 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 69.44 | 92.40 |
Price Performance
Historical ComparisonAbout BSM Black Stone Minerals L.P.
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests. The company owns mineral interests in approximately 16.9 million gross acres.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.